Trends in Cardiovascular Medicine
Volume 15, Issue 7 , Pages 265-271 , October 2005

Atheroprotective Effects of High-Density Lipoprotein-Associated Lysosphingolipids

  • Jerzy-Roch Nofer

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Jerzy-Roch Nofer, MD, MBA, Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Münster, Albert Schweizer Str 33, D-48129 Münster, Germany. Tel.: (+49) 251-835-6276; fax: (+49) 251-835-6276.
    • ,
  • Gerd Assmann

References 

  1. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem. 2004;279:20555–20558
  2. Assmann G, Nofer J-R. The protective role of HDL. In:  Carlson LA editors. Lectures in Clinical Atherosclerosis and Dyslipidemia. Part 3. London: Science Press; 2005;[Current Medical Group]
  3. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–2948
  4. Bolick DT, Srinivasan S, Kim KW, et al. Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol. 2005;25:976–981
  5. Brewer HB, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1755–1760
  6. Calabresi L, Rossoni G, Gomaraschi M, et al. High-density lipoproteins protect isolated rat hearts from ischemia–reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res. 2003;92:330–337
  7. Clair T, Aoki J, Koh E, et al. Autotoxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 2003;63:5446–5453
  8. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108–112
  9. Cuzzocrea S, Dugo L, Patel NS, et al. High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock. 2004;21:342–351
  10. Davaille J, Gallois C, Habib A, et al. Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem. 2000;275:34628–34633
  11. Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976;17:125–131
  12. Erren M, Reinecke R, Junker R, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999;19:2355–2363
  13. Haidar B, Denis M, Marcil M, et al. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem. 2004;279:9963–9969
  14. Hara A, Taketomi T. Occurrence of sulfatide as a major glycosphingolipid in WHHL rabbit serum lipoproteins. J Biochem. 1987;102:83–92
  15. Hedrick C. Lipid-mediated regulation of endothelial activation in atherosclerosis. In: 6th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, American Heart Association, Washington, DC. 2005;
  16. Hersberger M, von Eckardstein A. Low high density lipoprotein cholesterol—physiological background, clinical importance and drug treatment. Drugs. 2003;63:1907–1945
  17. Higuchi K, Hara J, Okamoto R, et al. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J. 2000;350:747–756
  18. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321–354
  19. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276:31780–31785
  20. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003;23:1283–1288
  21. Kostenis E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for “old” ligands. J Cell Biochem. 2004;92:923–936
  22. Liliom K, Sun G, Bunemann M, et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J. 2001;355:189–197
  23. Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol. 2002;13:523–529
  24. Marcil M, Bissonnette R, Vincent J, et al. Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiency. Circulation. 2003;107:1366–1371
  25. McDonald MC, Dhadly P, Cockerill GW, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock. 2003;20:551–557
  26. Mineo C, Yuhanna IS, Quon MJ, et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142–9149
  27. Miura S, Fujino M, Matsuo Y, et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:802–808
  28. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;3:809–815
  29. Nofer JR, Fobker M, Hobbel G, et al. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry. 2000;39:15199–15207
  30. Nofer JR, Junker R, Pulawski E, et al. High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost. 2001;85:730–735
  31. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001;276:34480–34485
  32. Nofer J-R, Kehrel B, Fobker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1–16
  33. Nofer JR, Geigenmuller S, Gopfert C, et al. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun. 2003;310:98–103
  34. Nofer JR, Van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569–581
  35. Norata GD, Callegari E, Inoue H, et al. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol. 2004;24:871–877
  36. Norata GD, Callegari E, Marchesi M, et al. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation. 2005;111:2805–2811
  37. Okamoto H, Takuwa N, Gonda K, et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem. 1998;273:27104–27110
  38. Okamoto H, Takuwa N, Yatomi Y, et al. EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16. Biochem Biophys Res Commun. 1999;260:203–208
  39. Porn MI, Akerman KE, Slotte JP. High-density lipoproteins induce a rapid and transient release of Ca2+ in cultured fibroblasts. Biochem J. 1991;279:29–33
  40. Ramet ME, Ramet M, Lu Q, et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol. 2003;41:2288–2297
  41. Ridker PM. High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–1818
  42. Spiegel S, Milstein S. Sphingosine 1-phosphate: an enigmatic signaling lipid. Nat Rev Mol Cell Biol. 2003;4:397–407
  43. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402
  44. Tamama K, Okajima F. Sphingosine 1-phosphate signaling in atherosclerosis and vascular biology. Curr Opin Lipidol. 2002;13:489–495
  45. Tamama K, Tomura H, Sato K, et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis. 2005;178:19–23
  46. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem. 2004;279:7622–7628
  47. Thiemermann C, Patel NS, Kvale EO, et al. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14:1833
  48. Toda K, Kobayashi T, Goto I, et al. Lysosulfatide (sulfogalactosylsphingosine) accumulation in tissues from patients with metachromatic leukodystrophy. J Neurochem. 1990;55:1585–1591
  49. Van Koppen C, Meyer zu Heringdorf M, Laser KT, et al. Activation of a high affinity G protein-coupled plasma membrane receptor by sphingosine-1-phosphate. J Biol Chem. 1996;271:2082–2087
  50. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002;106:1127–1132
  51. Walter M, Reinecke H, Nofer JR, et al. HDL3 stimulates multiple signaling pathways in human skin fibroblasts. Arterioscler Thromb Vasc Biol. 1995;15:1975–1986
  52. Xin C, Ren S, Kleuser B, et al. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem. 2004;279:35255–35262
  53. Yamazaki Y, Kon J, Sato K, et al. Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway. Biochem Biophys Res Commun. 2000;268:583–589
  54. Yuan Y, Jackson SP, Newnham HH, et al. An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2. Blood. 1995;86:4166–4274
  55. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–857
  56. Zhang B, Tomura H, Kuwabara A, et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis. 2005;178:199–205

PII: S1050-1738(05)00154-4

doi: 10.1016/j.tcm.2005.08.005

Trends in Cardiovascular Medicine
Volume 15, Issue 7 , Pages 265-271 , October 2005

Article Tools

* Image Usage & Resolution